Efficacy and safety analysis of hypofractionated and conventional fractionated radiotherapy in postoperative breast cancer patients.
Breast cancer
Conventional fractionated radiotherapy
Hypofractionated radiotherapy
Meta-analysis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Feb 2024
06 Feb 2024
Historique:
received:
15
06
2023
accepted:
24
01
2024
medline:
8
2
2024
pubmed:
7
2
2024
entrez:
6
2
2024
Statut:
epublish
Résumé
In this meta-analysis, we conducted a comparative analysis of the safety and efficacy of hypofractionated and conventional fractionated radiotherapy in individuals who had undergone surgery for breast cancer. This study involved a systematic and independent review of relevant research articles published in reputable databases such as PubMed, Embase, Cochrane Library, and Web of Science. Two investigators conducted the review, which included studies published up to January 3, 2023. The quality of the eligible studies was evaluated and data were extracted using Review Manager software 5.4 (RevMan 5.4) to calculate odds ratios (ORs) and 95% confidence intervals (CIs). The analysis comprised 35 studies and encompassed a collective sample of 18,246 individuals diagnosed with breast cancer. We did not find a statistically significant disparity in efficacy between conventional fractionated (CF) radiotherapy and hypofractionated (HF) radiotherapy regarding local recurrence (LR; OR = 0.91, 95% CI: 0.76-1.09, P = 0.30), disease-free survival (DFS; OR = 1.20, 95% CI: 1.01-1.42, P = 0.03), and overall survival (OS; OR = 1.08, 95% CI: 0.93-1.26, P = 0.28). Concerning safety, there was no significant difference between the HF and CF regimens in terms of breast pain, breast atrophy, lymphedema, pneumonia, pulmonary fibrosis, telangiectasia, and cardiotoxicity. However, the HF regimen resulted in lower skin toxicity (OR = 0.43, 95% CI: 0.33-0.55, P < 0.01) and improved patient fatigue outcomes (OR = 0.73, 95% CI: 0.60 - 0.88, P < 0.01). Although there is no substantial difference in LR, DFS, OS, or many other side effects between the HF and CF regimens, the HF regimen reduces skin toxicity and relieves patient fatigue. If these two issues need to be addressed in clinical situations, the HF regimen may be a superior alternative to conventional radiotherapy in postoperative breast cancer patients.
Identifiants
pubmed: 38321381
doi: 10.1186/s12885-024-11918-2
pii: 10.1186/s12885-024-11918-2
pmc: PMC10845660
doi:
Types de publication
Meta-Analysis
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181Subventions
Organisme : the Key Research and Development Projects of Shaanxi Province, China
ID : No. 2023-YBSF-503
Organisme : Xi'an Central Hospital Scientific Research Project
ID : No. 2022YB03. and No. 2022QN06
Organisme : Xi'an Innovation Capability Strong Foundation Project
ID : No. 21XYJ0021.
Informations de copyright
© 2024. The Author(s).
Références
JAMA Oncol. 2015 Oct;1(7):918-30
pubmed: 26247417
Radiat Oncol. 2010 Nov 23;5:112
pubmed: 21092288
Front Oncol. 2022 Apr 21;12:845037
pubmed: 35530354
Lancet Oncol. 2019 Mar;20(3):352-360
pubmed: 30711522
J Clin Diagn Res. 2016 Aug;10(8):XC01-XC03
pubmed: 27656543
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
Radiother Oncol. 2016 Jul;120(1):114-8
pubmed: 27046390
Strahlenther Onkol. 2021 Apr;197(4):281-287
pubmed: 33211138
J Natl Cancer Inst. 1959 Apr;22(4):719-48
pubmed: 13655060
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Strahlenther Onkol. 2005 Oct;181(10):625-31
pubmed: 16220400
Asia Pac J Oncol Nurs. 2018 Jan-Mar;5(1):107-113
pubmed: 29379842
Pract Radiat Oncol. 2018 May - Jun;8(3):145-152
pubmed: 29545124
Lancet Oncol. 2020 May;21(5):685-698
pubmed: 32203696
Lancet. 2011 Nov 12;378(9804):1707-16
pubmed: 22019144
JAMA Oncol. 2015 Oct;1(7):931-41
pubmed: 26247543
Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):445-456
pubmed: 34610389
Lancet. 2022 Aug 6;400(10350):431-440
pubmed: 35934006
Curr Opin Oncol. 2001 Jul;13(4):242-8
pubmed: 11429481
N Engl J Med. 2018 Nov 15;379(20):1937-1944
pubmed: 30428297
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Int J Radiat Oncol Biol Phys. 2022 Jul 1;113(3):561-569
pubmed: 35227790
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Clin Oncol (R Coll Radiol). 2015 May;27(5):260-9
pubmed: 25797579
Surg Oncol. 2015 Sep;24(3):200-11
pubmed: 26116397
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
Front Oncol. 2021 Oct 01;11:753209
pubmed: 34660318
Radiother Oncol. 2005 Apr;75(1):9-17
pubmed: 15878095
Breast Care (Basel). 2016 Oct;11(5):328-332
pubmed: 27920625
J Med Imaging Radiat Oncol. 2016 Jun;60(3):407-13
pubmed: 27258169
BMC Cancer. 2013 May 07;13:230
pubmed: 23651532
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Clin Oncol (R Coll Radiol). 2001;13(2):71-81
pubmed: 11373882
Med Sci Monit. 2015 Aug 03;21:2251-6
pubmed: 26235604
J Clin Oncol. 2018 Oct 31;:JCO1800317
pubmed: 30379626
Clin Breast Cancer. 2012 Feb;12(1):57-62
pubmed: 22056970
J Clin Oncol. 2020 Nov 1;38(31):3604-3614
pubmed: 32780661
Int J Radiat Oncol Biol Phys. 2020 Aug 1;107(5):943-948
pubmed: 32334033
J Thorac Dis. 2017 Oct;9(10):3840-3850
pubmed: 29268393
JAMA. 2014 Dec 17;312(23):2542-50
pubmed: 25494006
Radiat Oncol. 2016 Jul 30;11:100
pubmed: 27473272
Lancet. 2008 Mar 29;371(9618):1098-107
pubmed: 18355913
Lancet Oncol. 2008 Apr;9(4):331-41
pubmed: 18356109
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):71-8
pubmed: 22079722
Medicine (Baltimore). 2016 May;95(19):e3320
pubmed: 27175630
Adv Radiat Oncol. 2018 Nov 01;4(2):261-267
pubmed: 31011671
J Formos Med Assoc. 2022 Aug;121(8):1588-1595
pubmed: 35094914
BMJ Open. 2022 Sep 1;12(9):e062034
pubmed: 36581983
J Clin Oncol. 2020 Nov 1;38(31):3615-3625
pubmed: 32910709
Jpn J Clin Oncol. 2008 May;38(5):334-8
pubmed: 18417501
Breast J. 2017 Sep;23(5):563-568
pubmed: 28252236
PLoS One. 2021 Oct 7;16(10):e0258186
pubmed: 34618862
Clin Oncol (R Coll Radiol). 2021 Mar;33(3):e166-e171
pubmed: 33309183
Med Oncol. 2012 Dec;29(4):2570-6
pubmed: 22354766
Breast. 2017 Jun;33:57-70
pubmed: 28282588
Int J Radiat Oncol Biol Phys. 2021 Oct 1;111(2):360-370
pubmed: 33992718
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2086-92
pubmed: 21477936
Front Oncol. 2022 Aug 26;12:920739
pubmed: 36091145
Dement Geriatr Cogn Disord. 2001 May-Jun;12(3):232-6
pubmed: 11244218
Clin Oncol (R Coll Radiol). 2006 Apr;18(3):166-78
pubmed: 16605047
Breast. 2019 Dec;48:24-31
pubmed: 31476695
Nat Rev Cancer. 2006 Sep;6(9):702-13
pubmed: 16929324
N Engl J Med. 2013 Mar 14;368(11):987-98
pubmed: 23484825
Radiother Oncol. 2020 May;146:172-179
pubmed: 32171945